Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68.
Canine mammary carcinoma is a highly metastatic tumor that is poorly responsive to available treatment. Therefore, there is an urgent need to identify novel agents for therapy of this disease. Recently, we reported that the oncolytic vaccinia virus GLV-1h68 could be a useful tool for therapy of canine mammary adenoma in vivo. In this study we analyzed the therapeutic effect of GLV-1h68 against canine mammary carcinoma. Cell culture data demonstrated that GLV-1h68 efficiently infected and destroyed cells of the mammary carcinoma cell line MTH52c. Furthermore, after systemic administration, this attenuated vaccinia virus strain primarily replicated in canine tumor xenografts in nude mice. Finally, infection with GLV-1h68 led to strong inflammatory and oncolytic effects resulting in significant growth inhibition of the tumors. In summary, the data showed that the GLV-1h68 virus strain has promising potential for effective treatment of canine mammary carcinoma.
Gentschev
Ivaylo
I
Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA.
Ehrig
Klaas
K
Donat
Ulrike
U
Hess
Michael
M
Rudolph
Stephan
S
Chen
Nanhai
N
Yu
Yong A
YA
Zhang
Qian
Q
Bullerdiek
Jörn
J
Nolte
Ingo
I
Stritzker
Jochen
J
Szalay
Aladar A
AA